Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
Related to this article
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Perioperative Nivolumab Plus Neoadjuvant Chemotherapy Misses Co-Primary End Points in Muscle-Invasive Bladder Cancer
2
Teclistamab Monotherapy Wins EU Approval for R/R Myeloma After at Least 1 Prior Therapy
3
Dr Nghiemphu on How the NCCN Inclusion of Brigatinib Expands Access for NF2-Related Schwannomatosis
4
Adding UV1 Vaccine to Olaparib/Durvalumab Maintenance Misses PFS End Point in BRCA-Wild Type Recurrent Ovarian Cancer
5